Search company, investor...

Compare CellFree Sciences vs Genocea Biosciences

Customers evaluate the quality of CellFree Sciences's products using the following success metrics.

Overview

CellFree Sciences is based in Japan

ENDEXT Technology signifies the wheat germ cell-free protein synthesis technology that was developed by Professor Yaeta Endo of Ehime University. The wheat germ lysate produced by the technology is free of translation inhibitors, and as a result, it permits remarkably stable in vitro protein synthesis: all that is needed for the synthesis is to add the target mRNA as well as the amino acids and other substrates to the lysate. The eukaryotic origin of the ENDEXT(R) wheat germ lysate has made it possible to produce a broad range of difficult-to-express proteins including not only those of microorganisms and higher forms of life but also artificial proteins. Pacific Northwest National Laboratory (PNNL), one of the nine national laboratories of the U.S. Department of Energy, employed the CFS automatic protein synthesizer GenDecoder1000. PNNL will use it to synthesize proteins required for Genomes to Life (GTL) program, whose focus is on the molecular machines of DOE-relevant microbes and their networking in living cells and microbial communities. GenDecoder1000 is capable of transcription and translation of 384 samples in an overnight campaign.

Genocea Biosciences is 18 yrs old and is based in United States.

Genocea Biosciences (NASDAQ: GNCA) operates a biopharmaceutical company. It develops vaccines and immunotherapies using a transformational technology platform for T-cell antigen discovery. It offers immunotherapy for the treatment of genital herpes. The company was founded in 2006 and is based in Cambridge, Massachusetts.

Country

United States

Demo Video

Demo not available because CellFree Sciences has not claimed their profile.

Work for CellFree Sciences? Show off your product.

Demo not available because Genocea Biosciences has not claimed their profile.

Work for Genocea Biosciences? Show off your product.

Leadership

David A. Sinclair (Founder)

See all 5 people

Funding

Genocea Biosciences last raised $66M on 2/5/2014.

Investors

Mitsubishi UFJ Capital

Polaris Partners, Lux Capital

See all 5 investors

Product

Benefits

Products

Customers

Known Partners

Why They Buy

Information not available because CellFree Sciences has not claimed their profile.

Work for CellFree Sciences? Claim your profile by submitting an Analyst Briefing. By submitting you can

Show your primary competitive advantage
Highlight your competitive differentiation
Show why customers evalute your products
Explain why customers choose your products and services

Work for CellFree Sciences?

Claim your profile now.

Information not available because Genocea Biosciences has not claimed their profile.

Work for Genocea Biosciences? Claim your profile by submitting an Analyst Briefing. By submitting you can

Show your primary competitive advantage
Highlight your competitive differentiation
Show why customers evalute your products
Explain why customers choose your products and services

Work for Genocea Biosciences?

Claim your profile now.